This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05252/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05252/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05252/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05252/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB05252/identifier/drugbank/

Statements

Subject Item
n2:DB05252
rdf:type
n3:Drug
n3:description
ACCLAIM (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance. ACCLAIM treat chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart.
n3:group
investigational
n3:indication
Chronic angina and Coronary Artery Disease
owl:sameAs
n7:DB05252
dcterms:title
ACCLAIM
adms:identifier
n9:C11024 n10:192343 n11:47938 n12:43609 n13:DB05252
n3:mechanismOfAction
ACCLAIM is a proprietary combination of nitrate and L-arginine that provides the beneficial cardiovascular effects of nitrates. Combining L-arginine with organic nitrates prevents the endothelial cell's depletion of L-arginine and the associated problem of nitrate tolerance. By eliminating nitrate tolerance, ACCLAIM allows patients to receive the continuous, 24-hour benefit of a potent nitrate product, thus sustaining the desired vasodilation effect.
n3:IUPAC-Name
n4:271B3F20-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F26-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F25-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F22-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F23-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F24-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F1E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F1C-363D-11E5-9242-09173F13E4C5 n4:271B3F1F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F1D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B3F2C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F2D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F27-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F28-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F2A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F29-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F2B-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:Bioavailability
n4:271B3F31-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F33-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F34-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F30-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F2F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F32-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F21-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F2E-363D-11E5-9242-09173F13E4C5